Effect of dose timing in relation to food intake on systemic exposure to blonanserin

European Journal of Clinical Pharmacology

Volumn 66, Issue 9, 2010, Pages 899-902

  Saruwatari, Junji ^a,b   Yasui Furukori, Norio ^a   Inoue, Yoshimasa ^c   Kaneko, Sunao ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c MP Techno Pharma   (Japan)

Author keywords

Blonanserin; Dopamine D2 and serotonin 5 HT2 antagonist; Food; Systemic exposure; Time

Indexed keywords

BLONANSERIN; DOPAMINE 2 RECEPTOR BLOCKING AGENT; SEROTONIN 2 ANTAGONIST;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG HALF LIFE; FEMALE; FOOD DRUG INTERACTION; FOOD INTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; JAPANESE; LATENT PERIOD; MALE; MAXIMUM PLASMA CONCENTRATION; MENTAL CONCENTRATION; NORMAL HUMAN; OPEN STUDY; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL AVAILABILITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; EATING; FASTING; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; MALE; PIPERAZINES; PIPERIDINES; POSTPRANDIAL PERIOD; REFERENCE VALUES; RESEARCH DESIGN; TIME FACTORS;

EID: 77956186378     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0834-1     Document Type: Article

References (14)

1. CE Heading 1998 AD-5423 (Dainippon Pharmaceutical Co Ltd) IDrugs 1 7 813 817 1:STN:280:DC%2BD1czgtlOgtw%3D%3D 18465651
2. Dainippon Sumitomo Pharma Co., Ltd (2009) Lonasen® (blonanserin). Interview form (in Japanese). http://ds-pharma.jp/medical/product/dbps-data/- material-/product/lonasen/lonasen-tabpow-interv.pdf Accessed 8 March 2010
3. E Garcia M Robert, et al. 2009 The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study CNS Drugs 23 7 615 625 10.2165/00023210-200923070-00006 1:CAS:528:DC%2BD1MXpvFeitbw%3D 19552488
4. R Kumagai Y Ichimiya 2009 Efficacy of blonanserin in combination therapy for treatment-resistant depression Psychiatry Clin Neurosci 63 4 593 594 19659567
5. S Jordan J Knight, et al. 2004 Monitoring adverse drug reactions: scales, profiles, and checklists Int Nurs Rev 51 4 208 221 10.1111/j.1466-7657.2004. 00251.x 1:STN:280:DC%2BD2crlvV2rug%3D%3D 15530161
6. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (2001) Guidance for industry: Statistical Approaches to Establishing Bioequivalence. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070241.pdf Accessed 8 March 2010
7. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (2002) Guidance for industry: Food-Effect Bioavailability and Fed Bioequivalence Studies. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070241.pdf Accessed 8 March 2010
8. BN Singh 1999 Effects of food on clinical pharmacokinetics Clin Pharmacokinet 37 3 213 255 10.2165/00003088-199937030-00003 1:CAS:528: DyaK1MXmsFKrsL0%3D 10511919
9. D Fleisher C Li, et al. 1999 Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications Clin Pharmacokinet 36 3 233 254 10.2165/00003088-199936030-00004 1:CAS:528:DyaK1MXivFSrt78%3D 10223170
10. N Yasui-Furukori T Takahata, et al. 2003 Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepam Br J Clin Pharmacol 55 4 382 388 10.1046/j.1365-2125.2003.01775.x 1:CAS:528:DC%2BD3sXktVWjsrY%3D 12680887
11. MB Sostek Y Chen, et al. 2007 Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole Br J Clin Pharmacol 64 3 386 390 10.1111/j.1365-2125.2007.02889.x 1:CAS:528:DC%2BD2sXhtFKis7zJ 17425628
12. MA Karsdal I Byrjalsen, et al. 2009 Influence of food intake on the bioavailability and efficacy of oral calcitonin Br J Clin Pharmacol 67 4 413 420 10.1111/j.1365-2125.2009.03371.x 1:CAS:528:DC%2BD1MXlvFSjurk%3D 19371314
13. W Kang K Kim, et al. 2008 Effect of food on systemic exposure to niflumic acid following postprandial administration of talniflumate Eur J Clin Pharmacol 64 10 1027 1030 10.1007/s00228-008-0524-4 1:CAS:528:DC%2BD1cXht1Sqs7jP 18607579
14. N Yasui-Furukori T Kondo, et al. 2002 Effect of dietary fat content in meals on pharmacokinetics of quazepam J Clin Pharmacol 42 12 1335 1340 10.1177/0091270002042012004 1:CAS:528:DC%2BD38XpsV2qt7k%3D 12463728